Access options
Subscribe to Journal
Get full journal access for 1 year
$499.00
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
References
- 1.
Shirts, B. H. & Parker, L. S. Changing interpretations, stable genes: responsibilities of patients, professionals, and policy makers in the clinical interpretation of complex genetic information. Genet. Med. 10, 778–783 (2008).
- 2.
David, K. L. et al. Patient re-contact after revision of genomic test results: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 21, 769–771 (2019).
- 3.
Carrieri, D. et al. Recontacting patients in clinical genetics services: recommendations of the European Society of Human Genetics. Eur. J. Hum. Genet. 27, 169–182 (2019).
- 4.
Knoppers, B. M., Thorogood, A. & Ma’n, H. Z. Relearning the 3R’s? Reinterpretation, recontact, and return of genetic variants. Genet. Med. 21, 2401–2402 (2019).
- 5.
Appelbaum, P. S., Parens, E., Berger, S. M., Chung, W. K. & Burke, W. Is there a duty to reinterpret genetic data? The ethical dimensions. Genet. Med. 22, 633–639 (2020).
- 6.
Marchant, G. et al. From genetics to genomics: facing the liability implications in clinical care. J. Law Med. Ethics 48, 11–43 (2020).
- 7.
Evans, B. J. Minimizing liability risks under the ACMG recommendations for reporting incidental findings in clinical exome and genome sequencing. Genet. Med. 15, 915–920 (2013).
- 8.
Foulkes, A. L. et al. Can clinical genetics laboratories be sued for medical malpractice? Ann. Health Law Life Sci. 29, 153–172 (2020).
- 9.
Rothstein, M. A. & Siegal, G. Health information technology and physicians’ duty to notify patients of new medical developments. Houston J. Health Law Policy 12, 96–136 (2012).
- 10.
Mello, M. M. Of swords and shields: the role of clinical practice guidelines in medical malpractice litigation. Univ. Pennsylvania Law Rev. 149, 645–710 (2001).
- 11.
Van Tassel, K. Harmonizing the Affordable Care Act with the three main systems of healthcare quality improvement: the tort, licensure, and hospital peer review hearing systems. Brooklyn Law Rev. 78, 883–928 (2013).
- 12.
Marchant, G., LeRoy, B., Clatch, L. & Clayton, E. W. Unjust timing limitation in genetic malpractice cases. Albany Law Rev. 83, 61 (2019).
- 13.
Burke, W. et al. Improving recommendations for genomic medicine: building an evolutionary process from clinical practice advisory documents to guidelines. Genet. Med. 21, 2431–2438 (2019).
- 14.
Stevens, Y. A., Senner, G. D. & Marchant, G. E. Physicians’ duty to recontact and update genetic advice. Pers. Med. 14, 367–374 (2017).
- 15.
Clinical Laboratory Improvement Advisory Committee (CLIAC) Next Generation Sequencing (NGS) Workgroup. Summary report. https://www.cdc.gov/cliac/docs/addenda/cliac0419/10a_NGS_Workgroup_Report.pdf (2019).
- 16.
42C.F.R. §§ 493.1105(3)-(6) (2020).
- 17.
Rehm, H. L. et al. ACMG clinical laboratory standards for next-generation sequencing. Genet. Med. 15, 733–747 (2013).
- 18.
Gargis, A. S., Kalman, L. & Lubin, I. M. Assuring the quality of next-generation sequencing in clinical microbiology and public health laboratories. J. Clin. Microbiol. 54, 2857–2865 (2016).
- 19.
Evans, B. J. HIPAA’s individual right of access to genomic data: reconciling safety and civil rights. Am. J. Hum. Genet. 102, 5–10 (2018).
- 20.
Evans, B. J., Dorschner, M. O., Burke, W. & Jarvik, G. P. Regulatory changes raise troubling questions for genomic testing. Genet. Med. 16, 799–803 (2014).
- 21.
RTI International & White, P. J. Privacy and security solutions for interoperable health information exchange: report on state medical record access laws (2009). https://www.healthit.gov/sites/default/files/290-05-0015-state-law-access-report-1.pdf.
- 22.
Williams, M. S. in Emery and Rimoin’s Principles and Practice of Medical Genetics and Genomics 315–325 (Elsevier, Cambridge, MA, 2019).
- 23.
Shortliffe, E. H. & Sepulveda, M. J. Clinical decision support in the era of artificial intelligence. JAMA 320, 2199–2200 (2018).
- 24.
Devarakonda, M. V. et al. Automated problem list generation and physicians perspective from a pilot study. Int. J. Med. Inform. 105, 121–129 (2017).
- 25.
Chisholm, C. et al. Reinterpretation of sequence variants: one diagnostic laboratory’s experience, and the need for standard guidelines. Genet. Med. 20, 365–368 (2018).
- 26.
Deverka, P. A. & Dreyfus, J. C. Clinical integration of next generation sequencing: coverage and reimbursement challenges. J. Law Med. Ethics 42(Suppl 1), 22–41 (2014).
- 27.
Pagan, J. A. et al. Genetic variant reinterpretation: economic and population health management challenges. Popul. Health Manag. https://doi.org/10.1089/pop.2020.0115 (2020).
- 28.
Nelson, S. C. & Fullerton, S. M. “Bridge to the literature”? Third-party genetic interpretation tools and the views of tool developers. J. Genet. Couns. 27, 770–781 (2018).
- 29.
Nelson, S. C., Bowen, D. J. & Fullerton, S. M. Third-party genetic interpretation tools: a mixed-methods study of consumer motivation and behavior. Am. J. Hum. Genet. 105, 122–131 (2019).
- 30.
Guerrini, C. J., Wagner, J. K., Nelson, S. C., Javitt, G. H. & McGuire, A. L. Who’s on third? Regulation of third-party genetic interpretation services. Genet. Med., 22, 4–11 (2020).
- 31.
Tandy-Connor, S. et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genet. Med. 20, 1515 (2018).
- 32.
Moscarello, T., Murray, B., Reuter, C. M. & Demo, E. Direct-to-consumer raw genetic data and third-party interpretation services: more burden than bargain? Genet. Med. 21, 539–541 (2019).
- 33.
Morgan, T. M. Genomic Screening: the mutation and the mustard seed. J. Law Med. Ethics 46, 541–546 (2018).
- 34.
ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet. Med. 17, 68–69 (2015).
- 35.
Kalia, S. S. et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SFv2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet. Med. 19, 249–255 (2017).
- 36.
The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 21, 1467–1468, (2019).
- 37.
Foulkes, A. L. et al. Can clinical genetics laboratories be sued for medical malpractice? Ann. Health Law Life Sci. 29, 153–172 (2020).
- 38.
Deignan, J. L. et al. Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 21, 1267–1270 (2019).
Acknowledgements
This article was funded in part by R01HG010365. E.W.C. received additional support from 5RM1HG009034. P.S.A. and W.K.C. received additional support from 5RM1HG007257.
Author information
Affiliations
Corresponding author
Ethics declarations
Author contributions
Conceptualization, research, and review and editing: E.W.C., P.S.A., W.K.C., G.E.M., J.L.R., B.J.E. Writing—original draft: E.W.C.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Clayton, E.W., Appelbaum, P.S., Chung, W.K. et al. Does the law require reinterpretation and return of revised genomic results?. Genet Med (2021). https://doi.org/10.1038/s41436-020-01065-x
Received:
Revised:
Accepted:
Published: